All In Biotech

Free tool

FAERS Monitor: Nemluvio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761391 or its brand name (Nemluvio, Nemolizumab-Ilto). Reports on generic versions are filed under their own applications.

Reports

15,930

Serious

1,068

7% of reports

Hospitalization

479

Death reported

156

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue5,792
  • device malfunction2,529
  • pruritus1,581
  • inappropriate schedule of product administration1,578
  • incorrect dose administered1,544
  • rash1,056
  • drug ineffective947
  • device use error658
  • dermatitis atopic556
  • headache505
  • eczema420
  • device leakage403
  • arthralgia357
  • dry skin349
  • intentional product use issue343

Reports by year received

View as table
YearReports
20202
20224
20236
2024161
20257,279
20268,478

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device malfunctionSignal2,52949.347.5115,593
product dose omission issueSignal5,79226.526.0141,320
device use errorSignal65825.523.615,174
dermatitis atopicSignal55614.113.06,677
device leakageSignal40312.411.24,173
inappropriate schedule of product administrationSignal1,57811.711.115,356
eczemaSignal42010.79.73,653
incorrect dose administeredSignal1,5449.08.610,994
pruritusSignal1,5815.55.25,823
intentional product use issueSignal3435.24.71,155
dry skinSignal3493.53.1610
rashSignal1,0563.23.01,629
arthralgia3571.11.06
headache5051.11.02
drug ineffective9470.90.93

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.